05 August 2020
Visiongain has launched a new pharma report Biochips Market Report 2020-2030: Forecasts by Product Type (DNA Chip, Protein Chip, Enzyme Chip, Lab-on-a-Chip), Fabrication Techniques (Microarray, Microfluidics), Analysis Methods (Electrophoresis, Luminescence, Mass Spectrometry, Electrical Signals, Magnetism), Applications (Molecular Analysis, Diagnostics, Non-Biological Usage), End-use (Biotech & Pharma, Hospitals & Diagnostics Centers, Academic & Research Institutes, Others), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). PLUS Profiles of Leading Biochips Companies and COVID-19 Impact Analysis.
This report evaluates the biochips market for the period, 2020-2030. The global biochips market is estimated to be worth US$ xx million in 2020 and is projected to reach US$ xx million in 2030 while growing at a CAGR of xx% over the forecast period from 2020 to 2030.
As the field of nanofluidic matures, fundamental discoveries are being applied to lab-on-a-chip analyses. The unique behavior of matter at the nanoscale is adding new functionality to devices that integrate nanopores or nanochannels allowing for single-molecule interactions or single-molecule DNA-sequencing.
Nanoelectronics has already reached the level of maturity needed for such biochips. Nevertheless, challenges came up regarding the combination of sensors with microarrays that allow users to look at thousands of genes or proteins in parallel in a single experiment. Novel magnetic sensors are used in combination with these DNA microarrays to improve a single molecule investigation of DNA and DNA/protein interactions.
“Conceptually, it is clear for all stakeholders in the health care segment as well in the biotechnological sector the benefits are evident since it will improve the speed and accuracy of diagnostics or analysis. Biochip technology is regarded as a key technology, ensuring the cost efficiency required. The technology is also gaining increasing significance as a 'diagnostic of the future'."
Industry Analyst, Visiongain 2020
Today’s methods for disease/cancer diagnostics require taking invasive samples to be sent to a clinical laboratory with specialized and expensive biotechnology equipment that runs time-consuming tests to get a report on the analysis of that sample. Accurate analysis requires a certain amount of time and sample and therefore, far away from today’s requirements for rapid diagnostics and treatment. Doctors and patients are expecting Point-of-Care multiple tests at the same time with increased efficiency and speed. This would allow doctors to decide quickly and in the early stages of disease for its treatment. In areas like cardiovascular diseases, cancer, and chronic illnesses, this would be a paramount tool increasing the success rate of both doctors and patients in treating a medical condition. On the other side, some biotechnology areas recognize the early stage of biochip developments and therefore, expect advances of areas like micro/nanofluidic, nanoelectronics, and biotech to influence biochips development that together with a processing unit provides accurate, local, fast and cheap analysis or diagnosis. Those specialized biotech areas include DNA applications (gene expression, SNP genotyping, agricultural and zoological biotechnology) and Protein microarray applications (expression profiling, proteomics, high throughput screening, and drug discovery).
Some of the major companies operating in the global biochips market are Illumina, Inc., Agilent Technologies, Danaher Corporation, Fluidigm Corporation, Perkin Elmer, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Merck KgaA, and Cellix, Ltd. among other prominent players.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.